<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000386229"><TermName>safingol</TermName><TermPronunciation>(SA-fin-gol)</TermPronunciation><TermDefinition><DefinitionText>A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called protein kinase inhibitors. Also called L-threo-dihydrosphingosine.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000713226" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;safingol&quot;" language="en" id="_3"/><MediaLink ref="CDR0000713225" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;safingol&quot;" language="es" id="_4"/><SpanishTermName>safingol</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer. Es un tipo de inhibidor de la proteína cinasa. También se llama L-tri-dihidroesfingosina.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2004-08-24</DateFirstPublished><DateLastModified>2006-10-12</DateLastModified></GlossaryTerm>
